{"entity":{"id":"nct07134205","kind":"trial","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of JMT101, fOLFIRI (5-FU, leucovorin, irinotecan) and regorafenib in colorectal cancer, run by Shanghai JMT-Bio Inc., not yet recruiting.","summary":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07134205 by Shanghai JMT-Bio Inc., with a registry enrolment figure of 252 participants, started 2025-10-01 and due to reach its primary completion in 2027-06-01. Interventions recorded: JMT101; Irinotecan; Regorafenib. Conditions listed: Metastatic Colorectal Cancer (mCRC). Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: \"Pathological diagnosis as metastatic colorectal adenocarcinoma, with RAS and BRAF wild-type and non-dMMR/MSI-H;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07134205","url":"https://clinicaltrials.gov/study/NCT07134205"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","kinase-inhibitors","topoisomerase-inhibitors"],"targets":[],"drugs":["jmt101","folfiri","regorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07134205","phase":"3","setting":"A Randomized, Open-label, Multicenter Phase III Clinical Study of JMT101 in Combination With Irinotecan in Third-line and Beyond Treatment of Metastatic Colorectal Cancer","sponsor":"Shanghai JMT-Bio Inc.","enrolled":252,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07134205/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"jmt101","kind":"drug","name":"JMT101","route":"/drugs/jmt101/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}